1314999-69-3

Basic information

• Product Name: (2S)-2-hydroxypropaniMidaMide hydrochloride
• Synonyms: (2S)-2-hydroxypropaniMidaMide hydrochloride;(2S)-2-Hydroxy-propaniMidaMide HCl;(2S)-2-Hydroxypropanimidamide hydrochloride (1:1);(S)-2-hydroxypropanimidamide hydrochloride
• CAS NO: 1314999-69-3
• Molecular Formula: C3H9ClN2O
• Molecular Weight: 124.56936
• Mol File: 1314999-69-3.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (2S)-2-hydroxypropaniMidaMide hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: (2S)-2-hydroxypropaniMidaMide hydrochloride(1314999-69-3)
• EPA Substance Registry System: (2S)-2-hydroxypropaniMidaMide hydrochloride(1314999-69-3)

Safety Data

• Hazardous Substances Data: 1314999-69-3(Hazardous Substances Data)

Usage

General Description

(2S)-2-hydroxypropanimidamide hydrochloride is a chemical compound that is used in the pharmaceutical industry as a potential therapy for neurological disorders, specifically for the treatment of Alzheimer's disease. It is a cholinesterase inhibitor, which means it works by preventing the breakdown of acetylcholine in the brain, a neurotransmitter that is important for memory and learning. (2S)-2-hydroxypropanimidamide hydrochloride has shown promise in preclinical studies for its ability to improve cognitive function, and there is ongoing research to further explore its potential therapeutic effects.

Upstream product

• 598-81-2 (R)-lactamide 

Downstream Products

• 299397-03-8 2-(1RS-Hydroxy-ethyl)-3H-pyrimidin-4-one 
• 1400807-77-3 C₁₃H₁₄N₂O₂ 

Relevant articles and documents

Sorbitol dehydrogenase inhibitors

This invention is directed to sorbitol dehydrogenase inhibitory compounds of the formula I, wherein R1, R2and R3are as defined in the specification. This invention is also directed to pharmaceutical compositions containing those compounds and methods of treating or preventing diabetic complications, particularly diabetic neuropathy, diabetic nephropathy, diabetic microangiopathy, diabetic macroangiopathy and diabetic cardiomyopathy by administering such compounds to a mammal suffering from diabetes and therefore at risk for developing such complications. This invention is also directed to pharmaceutical compositions comprising a combination of a compound of formula I of this invention with an aldose reductase inhibitor and to methods of treating or preventing diabetic complications therewith. This invention is also directed to pharmaceutical compositions comprising a combination of a compound of formula I of this invention with an NHE-1 inhibitor and to methods of treating cardiomyopathy and other heart-related problems therewith. This invention is also directed to certain intermediates used in the synthesis of the compounds of formula I and to processes for preparing those intermediates.